Paper Details

  1. Home
  2. Paper Details

Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.

Author: HigurashiTakuma, HondaYasushi, ImajoKento, KatoShingo, KatoTakayuki, KessokuTakaomi, KirikoshiHiroyuki, KobayashiTakashi, KubotaKazumi, NakajimaAtsushi, OgawaYuji, SaitoSatoru, TaguriMasataka, TomenoWataru, UsudaHaruki, WadaKoichiro, YamanakaTakeharu, YonedaMasato

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This paper outlines the protocol for a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of lubiprostone (LUB) versus placebo in suppressing gut permeability in patients with non-alcoholic fatty liver disease (NAFLD) and constipation. NAFLD, including non-alcoholic steatohepatitis (NASH), is a prevalent chronic liver disorder with progression linked to increased gut permeability and endotoxins. LUB, a type 2 chloride channel activator, acts as a laxative for constipation and has shown potential in reducing gut permeability and blood endotoxin levels in healthy volunteers. This study aims to explore the benefits of LUB for NAFLD/NASH patients.
Paper Details　
Original Abstract of the Article :
This paper reports the protocol of a randomised, double-blind, placebo-controlled study to test the efficacy, safety, and tolerability of lubiprostone (LUB) vs. placebo on suppressing gut permeability in non-alcoholic fatty liver disease (NAFLD) patients with constipation. NAFLD, including non-alcoh...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.cct.2018.04.002

データ提供：米国国立医学図書館（NLM）

Lubiprostone: A Potential Treatment for Non-Alcoholic Fatty Liver Disease

The field of [non-alcoholic fatty liver disease (NAFLD)] research is focused on identifying new and effective treatments. This study explores the potential of [lubiprostone] for treating [NAFLD] in patients with [constipation]. Lubiprostone is a [type 2 chloride channel activator] that has been shown to [suppress gut permeability] and reduce [blood endotoxin levels]. The researchers aim to determine whether [lubiprostone can suppress gut permeability in NAFLD patients with constipation].

The Promise of Lubiprostone

The researchers will conduct a [double-blind, placebo-controlled study] to compare the effects of [lubiprostone] to [placebo]. This carefully controlled design, like a compass guiding us through the desert of clinical research, will allow the researchers to determine whether [lubiprostone is effective] in treating [NAFLD] in patients with [constipation].

A New Hope for NAFLD Patients?

The study's findings could offer a [new approach] to managing [NAFLD]. Like a shimmering oasis in the vast desert of liver disease, lubiprostone holds the potential to improve the lives of patients with [NAFLD] and [constipation]. If the study proves successful, lubiprostone could become a valuable addition to the treatment arsenal for this growing health concern.

Dr.Camel's Conclusion

This study is a promising journey into the desert of [NAFLD] research. The researchers are seeking to uncover the potential of [lubiprostone] as a new treatment option for this complex disease. If successful, this could lead to improved outcomes for patients with [NAFLD] and [constipation]. The results of this study are eagerly anticipated.

Date :
  1. Date Completed 2019-10-17
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

29627620

DOI: Digital Object Identifier

10.1016/j.cct.2018.04.002

Related Literature

Article Analysis
・Effects of lubiprostone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.